Mixed Cardiogenic-Vasodilatory Shock: Current Insights and Future Directions

Abstract

This state-of-the-art review defines mixed cardiogenic–vasodilatory shock as overt hypotension with end-organ hypoperfusion arising from the combination of acute cardiac insufficiency (low cardiac output) and inappropriate systemic vasodilation, typically with normal or elevated filling pressures; it introduces a pragmatic three-group classification (cardiogenic-vasodilatory, vasodilatory-cardiogenic, and primary mixed shock), emphasizes invasive hemodynamic monitoring, and outlines management built around tailored inotrope–vasopressor strategies while noting scarce data for mechanical circulatory support and a pressing need for consensus definitions and targeted trials.

Key Points

1. Concept and hemodynamic profile Mixed shock is best conceptualized by the triad of low cardiac output, low systemic vascular resistance, and normal/elevated ventricular filling pressures, distinguishing it from classic cardiogenic shock and necessitating hemodynamic confirmation.
2. Proposed classification (three pathways) Patients reach a mixed state via (a) cardiogenic-vasodilatory shock (primary CS complicated by vasoplegia), (b) vasodilatory-cardiogenic shock (primary vasodilatory shock complicated by low output), or (c) primary mixed shock from a single insult (e.g., postcardiac arrest or postcardiotomy) that rapidly produces both myocardial dysfunction and vasoplegia.
3. Epidemiology and prognosis Mixed shock is common in contemporary CICUs and portends worse illness severity, resource use, and in-hospital mortality; low MAP and low SVR independently track with mortality, and up to one in five CS patients demonstrate pathophysiologic vasodilation or blunted pressor response.
4. Inflammation as a unifying driver Systemic inflammation (infectious or sterile) triggers inducible nitric oxide synthase, excess NO, endothelial/microvascular dysfunction, oxidative stress, and abnormal mitochondrial oxygen use, collectively mediating vasoplegia and worsening tissue perfusion despite macro-targets appearing acceptable.
5. Diagnosis and the role of invasive monitoring Given the dynamic and often conflicting clinical signs as patients evolve from one phenotype to another, pulmonary artery catheterization is the gold standard to measure cardiac output and calculate SVR, track responses in real time, and guide staged titration of therapies.
6. Screening for infection and secondary hits Because SIRS and sepsis are frequent in CS and strongly associated with mixed phenotypes and worse outcomes, clinicians should pursue cultures, imaging, and early empiric antimicrobials while reassessing for catheter/line sources and other triggers.
7. Fluid strategy After a small, carefully tested crystalloid challenge in patients without overt congestion, management should default to conservative/restrictive fluids, recognizing many vasodilatory-CS patients have already received substantial resuscitation and may require decongestion.
8. Vasoactive approach—separate the knobs Therapy should separately titrate inotropes to restore cardiac output and vasopressors to restore MAP, with norepinephrine favored first-line across mixed phenotypes for efficacy and safety, while minimizing drugs that aggravate vasodilation (e.g., inodilators) or sedation-related vasoplegia.
9. Second-line vasoconstrictors and adjuncts For persistent vasoplegia, add pure vasoconstrictors after cardiac output is adequate—vasopressin is generally preferred second-line; angiotensin-II can raise MAP in vasodilatory shock but is contraindicated in low-output states; stress-dose hydrocortisone may reduce pressor needs in select high-dose cases, whereas nitric oxide synthase inhibitors (e.g., methylene blue, hydroxocobalamin) are third-line rescue options that improve MAP/SVR without proven survival benefit.
10. Mechanical circulatory support (MCS) MCS raises flow and may aid selected patients when cardiogenic components predominate, but vasoplegia can blunt MAP gains; intra-aortic balloon pump is typically ineffective in low-SVR states, and VA-ECMO provides fixed flow that may still be insufficient without concurrent vasopressors—device choice should be PAC-guided and executed by a multidisciplinary shock team.

Conclusion

Mixed cardiogenic–vasodilatory shock represents a high-risk, heterogenous syndrome unified by low output plus vasoplegia and driven frequently by systemic inflammation, with outcomes worse than “pure” shock states; optimal care requires PAC-guided, phenotype-aware titration of inotropes and vasopressors, cautious fluids, judicious consideration of MCS, and rigorous evaluation for intercurrent infection—while the field urgently needs consensus definitions, sub-phenotyping, and randomized trials to identify disease-modifying strategies.

ACCESS FULL ARTICLE HERE

Discussion Questions

1. How should we operationalize a consensus definition (including hemodynamic thresholds) that is practical at the bedside yet specific enough for trials in mixed shock?
2. Which biomarker and echocardiographic profiles best identify treatable sub-phenotypes (e.g., inflammation-dominant vs cardiodepression-dominant) to guide targeted therapy?
3. What are the MAP and perfusion targets—and corresponding drug sequences—that optimize outcomes across the three mixed-shock pathways without increasing arrhythmia, ischemia, or microcirculatory harm?

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.